Spectrum of cognitive impairment in neurocysticercosis Differences according to disease phase
Carregando...
Citações na Scopus
40
Tipo de produção
article
Data de publicação
2012
Editora
LIPPINCOTT WILLIAMS & WILKINS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
MASSAROPPE, L.
CARAMELLI, P.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
NEUROLOGY, v.78, n.12, p.861-866, 2012
Resumo
Objectives: Cognitive decline related to neurocysticercosis (NC) remains poorly characterized and underdiagnosed. In a cross-sectional study with a prospective phase, we evaluated cognitive decline in patients with strictly calcified form (C-NC), the epidemiologically largest subgroup of NC, and investigated whether there is a spectrum of cognitive abnormalities in the disease. Methods: Forty treatment-naive patients with C-NC aged 37.6 +/- 11.3 years and fulfilling criteria for definitive C-NC were submitted to a comprehensive cognitive and functional evaluation and were compared with 40 patients with active NC (A-NC) and 40 healthy controls (HC) matched for age and education. Patients with dementia were reassessed after 24 months. Results: Patients with C-NC presented 9.4 +/- 3.1 altered test scores out of the 30 from the cognitive battery when compared to HC. No patient with C-NC had dementia and 10 patients (25%) presented cognitive impairment-no dementia (CIND). The A-NC group had 5 patients (12.5%) with dementia and 11 patients (27.5%) with CIND. On follow-up, 3 out of 5 patients with A-NC with dementia previously still presented cystic lesions with scolex on MRI and still had dementia. One patient died and the remaining patient no longer fulfilled criteria for either dementia or CIND, presenting exclusively calcified lesions on neuroimaging. Conclusions: Independently of its phase, NC leads to a spectrum of cognitive abnormalities, ranging from impairment in a single domain, to CIND and, occasionally, to dementia. These findings are more conspicuous during active vesicular phase and less prominent in calcified stages.
Palavras-chave
Referências
- Agapejev S, 2003, ARQ NEURO-PSIQUIAT, V61, P822
- American Psychiatric Association, 1994, DIAGN STAT MAN MENT
- Bertolucci PHF, 2001, ARQ NEURO-PSIQUIAT, V59, P532
- Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777
- CANELAS H. M., 1962, ARQ NEURO PSIQUIAT, V20, P1
- Carpio A, 2002, LANCET INFECT DIS, V2, P751, DOI 10.1016/S1473-3099(02)00454-1
- de Andrade DC, 2010, NEUROLOGY, V74, P1288, DOI 10.1212/WNL.0b013e3181d9eda6
- Del Brutto OH, 2001, NEUROLOGY, V57, P177
- EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905
- FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
- Forlenza OV, 1997, J NEUROL NEUROSUR PS, V62, P612, DOI 10.1136/jnnp.62.6.612
- Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7
- Garcia HH, 2011, CURR OPIN INFECT DIS, V24, P423, DOI 10.1097/QCO.0b013e32834a1b20
- Gongora-Rivera F, 2008, NEUROLOGY, V71, P1119, DOI 10.1212/01.wnl.0000326961.34868.5b
- Hewagama SS, 2010, MED J AUSTRALIA, V193, P246
- Lucato LT, 2007, AM J NEURORADIOL, V28, P1501, DOI 10.3174/ajnr.A0623
- MORRIS JC, 1989, NEUROLOGY, V39, P1159
- Nash TE, 2004, NEUROLOGY, V62, P1934
- Nitrini R, 2004, J INT NEUROPSYCH SOC, V10, P634, DOI 10.1017/S1355617704104062
- Nitrini R, 2005, ARQ NEURO-PSIQUIAT, V63, P720
- PFEFFER RI, 1982, J GERONTOL, V37, P323
- Ramirez-Bermudez J, 2005, ARCH NEUROCIEN, V10, P92
- Ramirez-Bermudez J, 2005, J NEUROL NEUROSUR PS, V76, P1164, DOI 10.1136/jnnp.2004.052126
- SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
- Sorvillo F, 2011, EMERG INFECT DIS, V17, P1, DOI 10.3201/eid1701.101210
- Sotelo J, 2010, ARCH MED RES, V41, P62, DOI 10.1016/j.arcmed.2009.12.003
- Stroop R. J., 1935, J EXP PSYCHOL, V18, P643, DOI [DOI 10.1037/H0054651, 10.1037/h0054651]
- TAVARES AR, 1993, BRIT J PSYCHIAT, V163, P839
- TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6
- Wechsler D., 1997, WECHSLER MEMORY SCAL